Severe Sunitinib-Induced Myelosuppression in a Patient with a CYP 3A4 Polymorphism

Severe Sunitinib-Induced Myelosuppression in a Patient with a CYP 3A4 Polymorphism

Sunitinib, an oral vascular endothelial growth factor receptor, is a first-line option for metastatic renal cell carcinoma and widely used in clinical practice. Despite the proven benefit of sunitnib in metastatic renal cell carcinoma, patients may suffer from a variety of adverse events including h...

Full description

Bibliographic Details
Main Authors: Patel, Nirav D., Chakraborty, Kanishka, Messmer, Garrett, Krishnan, Koyamangalath, Bossaer, John B.
Published: Digital Commons @ East Tennessee State University 2017
Subjects:
CYP 3A4
myelosuppression
pharmacogenetic
polymorphism
sunitinib
Pharmacy Practice
Medicinal and Pharmaceutical Chemistry
Pharmacy and Pharmaceutical Sciences
Online Access:https://dc.etsu.edu/etsu-works/2330
https://doi.org/10.1177/1078155217724863

Internet

https://dc.etsu.edu/etsu-works/2330
https://doi.org/10.1177/1078155217724863

Similar Items